Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239103 | 0.89 | RAF1 (0.54) | RAB9ANPC1SMN1; SMN2MAPTHTT | |
| SCHEMBL8368359 | 0.86 | MAPT (0.56) | SMN1; SMN2MAPTMEN1KMT2ARAF1 | |
| SCHEMBL4243355 | 0.85 | MEN1 (0.55) | RAB9ANPC1SMN1; SMN2MAPTHTT | |
| SCHEMBL4243486 | 0.84 | RAF1 (0.61) | RAB9ANPC1SMN1; SMN2MAPTHTT | |
| SCHEMBL31440788 | 0.84 | KMT2A (0.61) | MAPTHTTMEN1KMT2ARAF1 | |
| SCHEMBL3675685 | 0.82 | CHRNA7 (0.70) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL3476076 | 0.82 | RAF1 (0.61) | MAPTHTTMEN1KMT2ARAF1 | |
| SCHEMBL4247303 | 0.82 | MEN1 (0.64) | RAB9ASMN1; SMN2MAPTHTTMEN1 | |
| SCHEMBL8370028 | 0.82 | GRIK1 (0.65) | RAB9ANPC1SMN1; SMN2MAPTHTT | |
| SCHEMBL5445313 | 0.81 | RAF1 (0.60) | MAPTHTTMEN1KMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHCARE LLC | 2009-04-09 | — | — | US | claimed |
| JP-3887769-B2 | — | — | 2007-02-28 | — | — | JP | claimed |
| EP-1616865-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | Bayer Pharmaceuticals Corporation (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1042305-B1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | claimed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | claimed |
| JP-2001526276-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-7517880-B2 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHCARE LLC | 2009-04-09 | — | — | US | disclosed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1545535-A4 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | RAB9A 3273/4885NPC1 2972/4885SMN1; SMN2 3312/4885 |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | MAP2K2, MAPK1, MAP2K1 | RAB9A 3273/4885NPC1 2972/4885SMN1; SMN2 3312/4885 |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | RAB9A 3273/4885NPC1 2972/4885SMN1; SMN2 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.